Literature DB >> 29133568

Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.

Yu Mi Wi1,2, Kerryl E Greenwood-Quaintance1, Audrey N Schuetz1, Kwan Soo Ko3, Kyong Ran Peck4, Jae-Hoon Song4, Robin Patel5,6.   

Abstract

Although carbapenems are effective for treating serious multidrug-resistant Pseudomonas aeruginosa infections, carbapenem-resistant P. aeruginosa (CRPA) is now being reported worldwide. Ceftolozane-tazobactam (C/T) demonstrates activity against many multidrug-resistant isolates. We evaluated the activity of C/T and compared its activity to that of ceftazidime-avibactam (C/A) using a well-characterized collection of non-carbapenemase-producing CRPA isolates. Forty-two non-carbapenemase-producing CRPA isolates from a previous study (J. Y. Lee and K. S. Ko, Int J Antimicrob Agents 40:168-172, 2012, https://doi.org/10.1016/j.ijantimicag.2012.04.004) were included. All had been previously shown to be negative for blaIMP, blaVIM, blaSPM, blaGIM, blaSIM, and blaKPC by PCR. In the prior study, expression of oprD, ampC, and several efflux pump genes had been defined by quantitative reverse transcription-PCR. Here, antimicrobial susceptibility was determined by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Time-kill curve assays were performed using three C/T- and C/A-susceptible CRPA isolates. Among 42 non-carbapenemase-producing CRPA isolates, overall susceptibility to C/T was 95.2%, compared to 71.4%, 42.9%, 23.8%, 21.4%, and 2.4% for C/A, ceftazidime, piperacillin-tazobactam, cefepime, and meropenem, respectively. The C/T resistance rate was significantly lower than that of C/A among isolates showing decreased oprD and increased mexB expression (5.1% versus 25.6%, P = 0.025, and 4.3% versus 34.8%, P = 0.022, respectively). In time-kill curve studies, C/T was less bactericidal than C/A against an isolate with decreased oprD and increased ampC expression. C/T was active against 95.2% of non-carbapenemase-producing CRPA clinical isolates. No apparent correlation of C/T MIC values with specific mutation-driven resistance mechanisms was noted.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; carbapenem resistant; ceftolozane-tazobactam

Mesh:

Substances:

Year:  2017        PMID: 29133568      PMCID: PMC5740377          DOI: 10.1128/AAC.01970-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

Authors:  A Walkty; J A Karlowsky; H Adam; M Baxter; P Lagacé-Wiens; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

Review 2.  Options for treating carbapenem-resistant Enterobacteriaceae.

Authors:  Petros I Rafailidis; Matthew E Falagas
Journal:  Curr Opin Infect Dis       Date:  2014-12       Impact factor: 4.915

3.  Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  J Infect       Date:  2014-04-26       Impact factor: 6.072

4.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

5.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  M V Hayes; D C Orr
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

6.  Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge; Marina Warner
Journal:  Int J Antimicrob Agents       Date:  2009-05-09       Impact factor: 5.283

Review 7.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 8.  New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?

Authors:  H Wright; R A Bonomo; D L Paterson
Journal:  Clin Microbiol Infect       Date:  2017-09-08       Impact factor: 8.067

9.  Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.

Authors:  Ik Sung Choi; Yu Ji Lee; Yu Mi Wi; Byung Soo Kwan; Kae Hwa Jung; Woong Pyo Hong; June Myong Kim
Journal:  Int J Antimicrob Agents       Date:  2016-07-05       Impact factor: 5.283

10.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

View more
  19 in total

Review 1.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

Review 2.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 3.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

4.  Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.

Authors:  Dana J Holger; Nicholas S Rebold; Sara Alosaimy; Taylor Morrisette; Abdalhamid Lagnf; Ana Christine Belza; Ashlan J Kunz Coyne; Amer El Ghali; Michael P Veve; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2022-09-01

5.  1,4,6-trihydroxy-8-alkylated-9,10-anthraquinones with antibacterial activities from soil-derived Streptomyces sp. WS-13394.

Authors:  Zhaoyuan Wu; Manli Liu; Kui Li; Fang Liu; Fei Zhang; Yani Zhang; Kaimei Wang; Wei Fang
Journal:  J Antibiot (Tokyo)       Date:  2022-05-20       Impact factor: 3.424

Review 6.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

7.  Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Ayesha Khan; José M Munita; Lina Rivas; Manuel Alcalde-Rico; José R W Martínez; María Victoria Moreno; Pamela Rojas; Aniela Wozniak; Patricia García; Jorge Olivares-Pacheco; William R Miller; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.938

8.  Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019.

Authors:  Yu-Lin Lee; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2021-11-22       Impact factor: 5.938

Review 9.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

10.  CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime-Avibactam And Aztreonam-Avibactam.

Authors:  Hua Zou; Sen-Jie Xiong; Qiu-Xia Lin; Meng-Lu Wu; Si-Qiang Niu; Shi-Feng Huang
Journal:  Infect Drug Resist       Date:  2019-09-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.